Standl, Eberhard http://orcid.org/0000-0002-8667-633X
Stevens, Susanna R.
Lokhnygina, Yuliya
Bethel, M. Angelyn
Buse, John B. http://orcid.org/0000-0002-9723-3876
Gustavson, Stephanie M.
Maggioni, Aldo P.
Mentz, Robert J.
Hernandez, Adrian F.
Holman, Rury R. http://orcid.org/0000-0002-1256-874X
Clinical trials referenced in this document:
Documents that mention this clinical trial
Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol
https://doi.org/10.1136/bmjopen-2014-005942
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
https://doi.org/10.2337/ds16-0026
Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
https://doi.org/10.2337/dc18-2028
Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
https://doi.org/10.1016/j.clinthera.2014.11.008
Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) (Results)
https://doi.org/10.2337/dc19-0950
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
https://doi.org/10.1186/s12933-019-0942-x
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
https://doi.org/10.1016/j.ahj.2015.02.002
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
https://doi.org/10.2337/dc18-1871
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
https://doi.org/10.1016/j.ahj.2015.12.009
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
https://doi.org/10.1016/s0140-6736(12)61267-7
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
https://doi.org/10.2337/dc19-1065
Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
https://doi.org/10.1186/s12933-022-01555-z
Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL (Results)
https://doi.org/10.2337/dc19-1079